Four JAK Inhibitors Have Comparable Efficacy, Safety for RA
By Elana Gotkine HealthDay Reporter
FRIDAY, Dec. 1, 2023 -- For patients with rheumatoid arthritis, the efficacy and safety of four Janus kinase (JAK) inhibitors is comparable, according to a study published online Nov. 1 in Rheumatology.
Shinya Hayashi, M.D., from the Kobe University Graduate School of Medicine in Japan, and colleagues conducted a multicenter, retrospective study comparing the efficacy and safety of tofacitinib (TOFA), baricitinib (BARI), peficitinib, and upadacitinib in 622 patients in real-world clinical settings. In the four treatment groups, patient backgrounds were matched using propensity score-based inverse probability of treatment weighting.
The researchers found that among the four JAK inhibitor groups, the retention and discontinuation rates until six months after drug initiation did not differ significantly. Furthermore, no differences were seen in mean Clinical Disease Activity Index (CDAI) value, CDAI remission rate, or CDAI-low disease activity (LDA) rate at six months after drug initiation. Predictive factors for resistance to CDAI-LDA achievement for JAK inhibitor treatment included baseline CDAI (odds ratios, 1.09 for tofacitinib and 1.07 for baricitinib), baseline C-reactive protein (CRP; odds ratio, 1.32 for tofacitinib), baseline glucocorticoid dose (odds ratio, 1.18 for baricitinib), and number of previous biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs; odds ratio, 1.36 for baricitinib).
"Baseline CRP titer and CDAI were identified as predictive factors for resistance to LDA achievement with TOFA," the authors write. "Baseline glucocorticoid dose, baseline CDAI, and number of previous b/tsDMARDs were identified as the predictive factors with BARI."
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Early Rheumatoid Arthritis Tied to Hypertension
TUESDAY, Oct. 22, 2024 -- Patients with early rheumatoid arthritis (RA) have a high incidence of prevalent and incident hypertension, according to a study published online in the...
Patients With Rheumatoid Arthritis Frequently Have Persisting Pain
THURSDAY, Oct. 10, 2024 -- Patients with rheumatoid arthritis (RA) undergoing standard-of-care treatment frequently have persisting pain, according to a study published online...
Urine Albumin-to-Creatinine Ratio Indicates Risk in Rheumatoid Arthritis
THURSDAY, Oct. 10, 2024 -- For patients with rheumatoid arthritis (RA), urine albumin-to-creatinine ratio (ACR) is an independent risk factor indicating prognosis, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.